EMBL-EBI | Chemical Biology | ChEBI
Example searches: iron*, InChI=1S/CH4O/c1-2/h2H,1H3, caffeine | Advanced Search
CHEBI:6402 - leflunomide
| Formula | C12H9F3N2O2 |
| Net Charge | 0 |
| Average Mass | 270.210 |
| Monoisotopic Mass | 270.06161 |
| SMILES | Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1 |
| InChI | InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18) |
| InChIKey | VHOGYURTWQBHIL-UHFFFAOYSA-N |
| Wikipedia |
|---|
| Roles Classification |
|---|
| Biological Roles: | tyrosine kinase inhibitor Any protein kinase inhibitor that interferes with the action of tyrosine kinase. hepatotoxic agent A role played by a chemical compound exhibiting itself through the ability to induce damage to the liver in animals. EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor Any EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16). EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor An EC 1.3.98.* (oxidoreductase acting on CH-CH group of donors, with other, known, acceptors) inhibitor that interferes with the action of dihydroorotate oxidase (fumarate), EC 1.3.98.1 (formerly EC 1.3.3.1). pyrimidine synthesis inhibitor A pathway inhibitor that inhibits the synthesis of pyrimidine. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. |
| Applications: | prodrug A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. antineoplastic agent A substance that inhibits or prevents the proliferation of neoplasms. non-steroidal anti-inflammatory drug An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. immunosuppressive agent An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. antiparasitic agent A substance used to treat or prevent parasitic infections. |
| ChEBI Ontology |
|---|
| Outgoing Relation(s) |
| leflunomide (CHEBI:6402) has role antineoplastic agent (CHEBI:35610) |
| leflunomide (CHEBI:6402) has role antiparasitic agent (CHEBI:35442) |
| leflunomide (CHEBI:6402) has role EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor (CHEBI:68542) |
| leflunomide (CHEBI:6402) has role EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor (CHEBI:37153) |
| leflunomide (CHEBI:6402) has role hepatotoxic agent (CHEBI:50908) |
| leflunomide (CHEBI:6402) has role immunosuppressive agent (CHEBI:35705) |
| leflunomide (CHEBI:6402) has role non-steroidal anti-inflammatory drug (CHEBI:35475) |
| leflunomide (CHEBI:6402) has role prodrug (CHEBI:50266) |
| leflunomide (CHEBI:6402) has role pyrimidine synthesis inhibitor (CHEBI:68543) |
| leflunomide (CHEBI:6402) has role tyrosine kinase inhibitor (CHEBI:38637) |
| leflunomide (CHEBI:6402) is a (trifluoromethyl)benzenes (CHEBI:83565) |
| leflunomide (CHEBI:6402) is a isoxazoles (CHEBI:55373) |
| leflunomide (CHEBI:6402) is a monocarboxylic acid amide (CHEBI:29347) |
| IUPAC Name |
|---|
| 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide |
| INNs | Source |
|---|---|
| léflunomide | WHO MedNet |
| leflunomida | WHO MedNet |
| leflunomidum | WHO MedNet |
| leflunomide | WHO MedNet |
| Synonyms | Source |
|---|---|
| Leflunomide | KEGG COMPOUND |
| 5-Methyl-N-(4-(trifluoromethyl)phenyl)-4-isoxazolecarboxamide | ChemIDplus |
| 5-Methylisoxazole-4-carboxylic acid (4-trifluoromethyl)anilide | ChEBI |
| alpha,alpha,alpha-Trifluoro-5-methyl-4-isoxazolecarboxy-p-toluidide | ChemIDplus |
| Brand Name | Source |
|---|---|
| Arava | KEGG DRUG |
| Manual Xrefs | Databases |
|---|---|
| C07905 | KEGG COMPOUND |
| D00749 | KEGG DRUG |
| Leflunomide | Wikipedia |
| DB01097 | DrugBank |
| DE2854439 | Patent |
| US4284786 | Patent |
| HMDB0015229 | HMDB |
| LSM-3771 | LINCS |
| 1552 | DrugCentral |
| Registry Numbers | Sources |
|---|---|
| Reaxys:4323174 | Reaxys |
| CAS:75706-12-6 | KEGG COMPOUND |
| CAS:75706-12-6 | ChemIDplus |
| Citations |
|---|